



Berkshire West Area Prescribing Committee Policy Statement

Drug Name	Lomitapide (Lojuxta®)
Indication under review	Treatment of homozygous familial hypercholesterolaemia
Policy No:	APC 092
Date of Issue:	November 2014
Review Date:	November 2017
Policy Statement: Lomitapide (Lojuxta ®) is NOT recommended for treatment of homozygous familial hypercholesterolaemia in primary care. Funding of this treatment is through NHS England via specialist centres.	
Traffic Light Status	Brown
Key Points considered: <ul style="list-style-type: none"> • This is treatment is for a rare genetic disease and is currently managed by NHS England. • Annual cost of treatment is significant at £230,000 per annum 	
References: eMC Summary of Product Characteristics, accessed 25.03.2014 http://www.medicines.org.uk/emc/medicine/28513/SPC/Vipidia+6.25mg%2c+12.5mg%2c+25mg+film-coated+tablets/ • eMC Dictionary of Medicines and Devices Browser, accessed 25.03.2014 http://dmd.medicines.org.uk/DesktopDefault.aspx?AMPP=2363641100001100&toc=nofloat • Efficacy and Safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single arm, open-label, phase 3 study. Cuchel et al, The Lancet, Vol 381, January 5 2013, pgs 40-46 • Lomitapide for homozygous familial hypercholesterolaemia (Comment), The Lancet, Vol 381, January	
Date taken to APC:	5 th November 2014
Date Ratified by MMC on Behalf of the Board:	12 th November 2014